GlassScriptPhysician profile
Andrew S Delemos
NPI 1619098183
$44,158.85
in general payments reported to CMS, 2019-2025
14 companies · $14K in 2025
The $14K reported for 2025 was more than what 80% of Transplant Hepatology providers received nationally (typical 2025 total: $508).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $257 · 2020: $4,800 · 2021: $97.51 · 2022: $96.06 · 2024: $24K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Consulting Fee: $15K · Travel and Lodging: $2,376 · Food and Beverage: $1,287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,264.00 |
| Consulting Fee | $14,980.22 |
| Travel and Lodging | $2,376.38 |
| Food and Beverage | $1,287.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $23,974.88 | 2024-2025 | Rezdiffra, Resmetirom |
| Ipsen Biopharmaceuticals, INC | $14,480.22 | 2024 | Iqirvo |
| Takeda Pharmaceuticals U.S.A., INC. | $4,800.00 | 2020 | |
| Gilead Sciences, INC. | $322.98 | 2019-2024 | |
| Mallinckrodt Hospital Products INC. | $145.39 | 2025 | Terlivaz |
| Dilon Technologies, INC. | $137.50 | 2025 | Hemoblast Bellows |
| Boston Scientific Corporation | $119.70 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $97.51 | 2021 | |
| Siemens Medical Solutions USA, INC. | $80.67 | 2024 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Delemos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.